Introduction
The infectious origin of a number of human cancers is now well established. The best known associations among solid tumors are Helicobacter pylori with gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALT), Schistosoma with bladder (S. haematobium) and colon (S. mansoni) cancers, hepatitis B and C viruses (HBV, HCV) with hepatocarcinoma, and papilloma virus with cervical cancer. 1 In hematology, four viruses are known to be co-factors of malignant diseases in humans. Human T cell leukemia virus-1 (HTLV-1) is responsible for a T cell leukemia endemic in Japan.
1,2 Hepatitis C virus (HCV) is associated with mixed cryoglobulinemia, some lymphoplasmacytoid lymphoma, marginal zone lymphoma and diffuse large B cell lymphoma. 3, 4 The neoplastic potential of at least two human herpesviruses with B lymphocyte tropism, Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma herpes virus (KSHV or HHV-8) has been established, especially within the context of treatment with immunosuppressive agents or co-infection with human immunodeficiency virus (HIV). 1, 5, 6 EBV can induce Hodgkin and Burkitt's lymphoma and immunodeficiency-associated lymphoma observed in AIDS patients and graft recipients. 1, 5 HHV-8 is responsible for the induction of a particular type of lymphoma termed 'body-cavity' or primary-effusion lymphoma (PEL) and Castleman's disease. 1, 7, 8 The role played by HHV-6, a virus with T lymphocyte tropism but reportedly found in tumor cells of several patients with B cell lymphoma, is still uncertain. 9, 10 The potential involvement of HHVs in well-characterized hematological malignancies can be more precisely investigated using recently developed sensitive and quantitative methods, such as qPCR, 11, 12 to relate virus loads to disease emergence and progression. In addition, the increase in comparative sequence information of genes from various species has allowed the development of a number of nucleic acidbased approaches to search for additional HHV homologues. PCR using consensus-degenerate hybrid oligonucleotide primers (CODEHOP) 13, 14 for example, has provided a means for the identification of a number of new herpesviruses that are refractive to cell culture propagation. [15] [16] [17] The level of sophistication of new PCR approaches is sufficiently advanced to initiate a search for unidentified herpesviruses associated with malignant human cell proliferation. A new bovine herpesvirus, bovine lymphotropic herpes virus, BLHV, associated with persistent lymphocytosis, 17 a new marine turtle ␣-herpesvirus associated with fibropapillomatosis in sea turtles 16 and two HHV-8 homologs in retroperitoneal fibromatosis of different macaque species 15 were recently identified using CODEHOP PCR techniques. The CODEHOP PCR approach is at least three orders of magnitude more sensitive than the method described by Donehower et al. 18 The higher specificity and sensitivity is due primarily to the use of much longer primers containing a degenerate core and a consensus clamp, and the ability to run the reaction at either a higher temperature or with a temperature ramp.
We chose to begin this study with three categories of B cell malignancies of still unknown origin: child and adult B-cell acute lymphoblastic leukemia (B-ALL), B-cell chronic lymphocytic leukemia (B-CLL) and multiple myeloma (MM). Arguments for a viral etiology have been presented for these diseases. 19, 20 Our objectives were two-fold: first, to quantify virus loads of known HHVs capable of infecting lymphocytes (EBV, HHV-8, HHV-6 variants A and B, HHV-7) and also CMV using qPCR; second to search for the presence of new herpesviruses using CODEHOP PCR.
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Materials and methods
Patient samples
With the patients' and donors' informed consent, a total of 101 BM or blood samples were tested for HHV loads. Blood and BM samples of 61 patients with B cell malignancies (29 B-ALL, 13 children and 16 adults; 21 B-CLL; 11 multiple myeloma) were collected at diagnosis prior to treatment. Forty control samples were also collected: 16 acute myeloid leukemia (AML) and 28 samples from 24 healthy donors: 17 samples of peripheral blood lymphocytes (PBL), four samples of B lymphocytes purified from blood, four samples of CD34 + cells purified from blood or BM, and three samples of nonpurified BM. B lymphocytes and CD34 + cells were purified (Ն98% pure) according to the manufacturer's instructions with CD19 and CD34 MicroBead isolation kits (Miltenyi Biotec, Paris, France). Non-purified samples were submitted to Ficoll centrifugation to separate mononuclear cells, then kept frozen in liquid nitrogen until use. For B-ALL, B-CLL and AML patients, most samples contained at least 90% of tumor cells (blasts for B-ALL and AML, B lymphocytes for CLL). For MM patients, only samples with at least 50% plasma cells were collected. The median percentages of tumor cells before Ficoll separation varied from 76.5% (AML) to 96% (B-ALL), ensuring that after Ficoll centrifugation, almost all the cell preparations studied contained more than 90% tumor cells. The geographic area from which patients and healthy donors originated was Western France (B-ALL, B-CLL, AML, MM, healthy donors) but a few samples were from Portugal (B-ALL, healthy donors) and north eastern USA (healthy donors).
Cytomorphology and immunophenotyping
The diagnosis of each specimen was based on a comprehensive analysis of the clinical, morphological and immunophenotypical features. Blood and bone marrow smears and cytospins were stained by May-Grü nwald-Giemsa (MGG) and examined by direct microscopy. Immunophenotyping of tumoral cells was performed by multicolor flow cytometry analysis (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ, USA) using appropriate panels of monoclonal antibodies as previously described. [21] [22] [23] AML and B-ALL immunophenotypic profiles were classified according to the EGIL proposals (for B-ALL: B-I/pro-B (CD10 ) and B-IV/mature B (surface immunoglobulin or sIg + )). 21, 24 Diagnosis of B-CLL was established when the CLL score, including CD5, CD22, CD23, sIg and FMC7 antigen expression, was Ն4.
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DNA preparation
Pellets of BM or blood mononuclear cells (aliquots of 3 to 5 millions cells, except for aliquots of purified B lymphocytes or CD34
+ cells, which contained 1.5 to 2 millions cells) were thawed, washed in PBS and genomic DNA was prepared using QIAamp DNA mini-kits for blood and tissue samples (Qiagen, Valencia, CA, USA). DNA preparations were kept at 4°C until use for either qPCR or CODEHOP PCR.
Real-time quantitative PCR (qPCR)
qPCR was performed using the ABI 7700 Prism PCR instrument, with TaqMan reagents and fluorescent probes from ABI/Applied BioSystems, Foster City, CA, USA. Primers and probes specific for an 80-85 bp amplicon within the DNA polymerase gene of EBV, CMV, HHV-6 variants A and B, HHV-7 and HHV-8 were designed and are described in Table 1 .
Internal standards were made from each HHV's DNA polymerase amplicon, amplified from infected cell lines: AA2 for EBV, BCBL2 for HHV-8, HSB2/HHV-6 for HHV-6 (AIDS Repository), human fibroblasts for CMV, followed by cloning into TOPO-TA vector (InVitrogen, Carlsbad, CA, USA). For HHV-7, internals standards were made by hybridizing two 54-mer oligonucleotides corresponding to HHV-7 DNA polymerase (Table 1) , followed by PCR amplification with specific primers and cloning into the TOPO-TA vector. After verifying each clone by sequencing, DNA preparations of the TOPO-TA constructs containing EBV, CMV, HHV-6 A and B, HHV-7 and HHV-8 DNA polymerase amplicons were used as copy number standards for qPCR assays. The specificity, sensitivity and reproducibility of the qPCR assays were verified using DNA from cells known to be infected with the HHVs studied. The qPCR assays thus developed were mono-specific and highly sensitive (<10 copies of HHV DNA in 100 ng cellular DNA). They were fully reproducible for samples with copy numbers higher than 50. For samples with less than 50 copies/100 ng DNA, several independent qPCR amplifications were performed; samples were considered positive when at least two independent qPCR were positive. qPCR for each of the HHVs listed above were performed on 100 ng of DNA per reaction; this corresponds to approximately 15 000 cells assuming that each cell contains 6 pg of DNA. Amplification was performed in a reaction volume of 25 l for forty cycles (15 s at 95°C, 1 min at 60°C). Most samples were tested twice; samples with low copy numbers were tested at least twice. Results are expressed as mean numbers of copies of HHV DNA polymerase per 100 ng of cellular DNA.
HHV-8 v-cyclin nested PCR
A first round of PCR amplification was performed with outer primers 5Ј-TTCCTTCTTGTTACTTAAATTGCTGG-3Ј (forward primer, sequence position: 467-492 bp) and 5Ј-GAAACA-GATGTTAGGATCTGTTCCAC-3Ј (reverse primer, sequence position: 742-717 bp) on 100 ng of DNA per 50 l reaction. After 5 min at 94°C, the amplification program consisted of 30 s at 94°C, 20 s at 57°C and 20 s at 72°C for 35 cycles, followed by 5 min at 72°C. A second round of nested PCR was performed with inner primers 5Ј-CTCCCAA-CACCTGGACTTTTG-3Ј (forward primer, sequence position: 497-517 bp) and 5Ј-CGCCTGTAGAACGGAAACATC-3Ј (reverse primer, sequence position: 713-693 bp) with 2.5 l of the first PCR product in a 50 l reaction, following the same amplification program as the first PCR. The size of the final PCR product was 215 bp. PCR products were run on a 2.5% agarose gel and stained with ethidium bromide for UV visualization. PCR products of the predicted size were then extracted from the gel (Qiaex II kit; Qiagen), cloned into the TOPO-TA vector and sequenced at the BioResource Center, Cornell University. Amplicon sequences were analyzed by comparison to sequences available in NCBI BLAST search. EBV, HHV, CMV: Internal standards were made by amplification from infected cells of a 80-85 bp sequence of the DNA polymerase using PCR with primers specific for each virus. HHV-7: The internal standard was made by hybridization of two 54 bp oligonucleotides followed by PCR amplification with HHV-7-specific primers. HHV-6: The internal standard was made by PCR amplification from infected cells of a 150 bp sequence of the DNA polymerase with primers not distinguishing between types A and B. All PCR products were sequenced, and the equivalent of DNA copy numbers determined, to be used as internal standards for qPCR. qPCR reactions were performed with primers and probes specific for each virus. For HHV-6, the primers were specific for each subtype, but the probe was common, 100% identical to a common sequence of subtypes A and B. Orientation: +, sense; −, anti-sense.
HHV-6A DNA polymerase PCR
PCR amplification was performed with HHV-6A primers 5Ј-GTTGTCCTCTGTGCTTTCCAAA-3Ј (forward primer, sequence position: 2657-2678 bp) and 5Ј-GCCAATA-GATGGTGCTATTAACACG-3Ј (reverse primer, sequence position: 2808-2784 bp) on 100 ng of DNA per 50 l reaction. After 5 min at 94°C, the amplification program consisted of 30 s at 94°C, 20 s at 57°C and 20 s at 72°C for 35 cycles, followed by 5 min at 72°C. The size of the final PCR product was 152 bp. PCR products were isolated, cloned and sequenced as described above.
CODEHOP PCR
To reveal any novel HHVs, DNA samples found negative for HHVs by qPCR were analyzed by CODEHOP PCR with primer pools designed to recognize all HHVs, as described. 15 These primers were modeled on consensus amino acid sequences in the most conserved gene in herpesviruses, DNA polymerase, with a consensus 5Ј clamp and a degenerate 3Ј sequence. [15] [16] [17] The primers were slightly modified to bring them closer to the sequences of the known HHVs ( Table 2) .
The HHV CODEHOP PCRs were performed on 100 ng of DNA and, occasionally, on both 100 ng and 1 g of DNA. A semi-nested PCR reaction was performed, using first 100 Leukemia pmoles of either DFAS (␥/␣ herpesviruses) or DFQS (␤ herpesviruses) and GDTD primers (55°C or 60°C, 35 cycles). Then, 2% of the PCR reaction was subjected to a second amplification using 100 pmoles of TCNAVYG and GDTD primers, under the same conditions. The primers were tested on DNA extracted from cells infected with a known number of the different HHVs (determined by qPCR). Under the conditions used, the lowest number of viral copies detected with the sets of primers DFAS/GDTD and TCNAVYG/GDTD was 10 for EBV and HHV-8, 100 for CMV and 1000 for HHV-6 (data not shown). Products of CODEHOP PCR directed at amplifying HHV polymerase amplicons were separated on 2.8% agarose gels (the expected sizes of PCR products are approximately 225 bp for HHVs). PCR amplicons of the expected size were purified then cloned into TOPO-TA vector for sequencing. Amplicon sequences were analyzed by comparison to sequences of known viruses available in data banks (NCBI BLAST search).
Statistical analysis
Mann-Whitney's rank sum test was used to compare data of different groups of patients, and Fisher's exact test to compare proportions. A P value < 0.05 was considered statistically significant. GTG  GTG  TTC  GAC  TTT  GCC  AGC  CTG  TAC  CCC  EBV  GTT  CTG  GTG  GTG  GAC  TTT  GCC  AGC  CTG  TAC  CCG  HHV-8  GTA  CTC  GTG  GTG  GAT  TTT  GCC  AGC  TTG  TAC  CCC  CMV  GTG  GCC  GTG  TTC  GAC  TTT  GCC  AGC  CTC  TAC  CCT  HHV-6A  ACC  GTG  GTG  TTT  GAT  TTT  CAA  AGT  TTG  TAT  CCG  HHV-6B  ACT  GTG  GTG  TTT  GAT  TTT  CAG  AGT  TTG  TAT  CCG  HHV-7  ACA  GTA  GTT  TTT  GAT  TTC  CAA  AGT  TTG  TAT GTG  TGT  AAC  TCG  GTG  TAC  GGG  TTC  ACG  GGA  HSV-2  GTG  GTG  TGC  AAC  TCG  GTG  TAC  GGG  TTC  ACG  GGG  EBV  TGC  ACG  TGC  AAC  GCC  GTC  TAC  GGC  TTC  ACC  GGG  HHV-8  GTT  ACC  TGC  AAC  GCC  GTT  TAC  GGC  TTC  ACG  GGC  CMV  GTA  ACG  TGC  AAC  GCT  TTC  TAC  GGT  TTT  ACC  GGC  HHV-6A/B  ACA  ACA  TGT  AAC  TCG  GTG  TAC  GGT  GTC  ACG  GGA  HHV-7  ACT  ACT  TGT  AAT  TCA  GTC  TAC  GGA  GTC  ACC  GGG  (forward)  'TCNAVYG' primer  5Ј-GTA  ACG  TGC  AAC  GCG  GTG  TAC  GGN  KTN  ACN  GG-3Ј  Rose et al   15   5Ј-ACG  TGC  AAC  GCG  GTG  TAY  GGN  KTN  ACN  GG-3Ј   GDTD  YGDTDS  HSV-1/2  882  IIYGDTDSIFVLC  EBV  751  VIYGDTDSLFIEC  HHV-8  748  VIYGDTDSLLASI  CMV  906  VIYGDTDSVFVRF  HHV-6A/B  736  VIYGDTDSIFMSV  HHV-7 735 HSV-1  TAC  GGG  GAC  ACG  GAC  TCC  ATA  TTT  GTG  CTG  TGC  CGC  HSV-2  TAC  GGG  GAC  ACG  GAC  TCC  ATT  TTC  GTT  TTG  TGC  CGC  EBV  TAC  GGG  GAC  ACG  GAC  TCG  CTG  TTT  ATC  GAG  TGC  CGG  HHV-8  TAC  GGC  GAC  ACT  GAC  TCT  CTT  TTC  ATA  TGC  TGC  ATG  CMV  TAC  GGG  GAC  ACG  GAC  AGC  GTG  TTT  GTC  CGC  TTT  CGT  HHV-6A/B  TAT  GGT  GAT  ACG  GAT  AGC  ATC  TTT  ATG  TCT  GTC  AGA  HHV-7  TAT  GGT  GAT  ACT  GAC  AGT  CTT  TTT  GTT  ACT  TTC  AAA  (reverse)  'GDTD' primer  5Ј-CG  GAA  CGA  CAT  AAA  CAT  GGT  GTC  NGT  RTC  NCC  RTA-3Ј  Rose et al   15   5Ј-CG  GCA  TGC  GAC  AAA  CAC  GGA  GTC  NGT  RTC  NCC  RTA-3Ј CODEHOP PCR oligonucleotide primers for HHV DNA polymerases. Y = C+T; N = A+C+G+T; K = T+G; R = A+G; H = A+C+T; D = A+G+T.
Results
The presence and viral loads of EBV, HHV-8, CMV, HHV-7 and HHV-6 were studied by qPCR for the DNA polymerase of each HHV in preparations of tumor cells of 61 patients; data are detailed in Table 3 and analyzed in Table 4 . Generally, when HHV loads differed, they differed depending on age and type of disease, not origin (blood or bone marrow) nor percentage of tumor cells in sample.
Measurements of EBV and HHV-8 DNA loads
The presence and loads of EBV and HHV-8, ␥-herpesviruses known to be able to transform B cells, in tumor samples were distinct. For cells prepared from blood, all but one sample of PBLs or purified B lymphocytes from adult healthy donors were positive for EBV vs 36.4% of MM samples and 52.4% of B-CLL samples, but the differences were not statistically significant (Fisher's exact test). Bone marrow (BM) samples of healthy donors were all negative for EBV; in contrast, the majority of BM samples of B-ALL or AML patients were positive for EBV. EBV viral load was <100 copies/100 ng DNA in all samples of healthy donors and children with B-ALL, and in the majority of samples of adult patients with AML, MM, B-CLL or B-ALL. Overall, EBV loads for samples of B-ALL and B-CLL patients were not significantly different from EBV loads of control samples (PBL from healthy donors or AML samples) (Table 4) . However, two out of 21 (9.5%) samples of B-CLL patients and two out of 16 (12.5%) samples of adult B-ALL patients had loads of EBV >500 copies/100 ng DNA (up to 2200 copies/100 ng DNA). Most studies have concluded that rates of HHV-8 infection vary worldwide, less than 4% of the general population in western Europe being positive for HHV-8. 25, 26 In our series, all samples of children and 10 out of 11 samples from MM patients were negative for HHV-8. The high frequency of HHV-8 positivity (18.8% to 28.6%) of B-ALL, AML and B-CLL patients was unexpected. HHV-8 DNA loads in B-CLL and B-ALL samples were all Յ16 copies/100 ng DNA (Table 4) . When positive for HHV-8, AML samples had significantly higher loads. Among the MM samples, one sample from a patient diagnosed with plasma cell leukemia (PCL) had a very high load of HHV-8 (6.3 × 10 6 copies/100 ng DNA); this particular case, unusual by its clinical and biological presentation and the observation that his blasts were co-infected with another virus, is the object of a separate, detailed study. 
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Measurements of HHV-7 and HHV-6 DNA loads
As a proof of principle, the presence and viral loads of the two T cell tropic HHVs, HHV-6 and HHV-7 28,29 were also studied (Tables 3 and 4) . Two variants of HHV-6, types A and B, have been described. 29 In the general population, in Europe and in the USA, HHV-6B is twice as prevalent (70%) as HHV-6A (30%), whereas in Africa HHV-6A appears to be predominant. In addition to its T cell tropism, HHV-6 seems to be capable of infecting B cells, as well as hematopoietic progenitors. 30 Six samples from 17 healthy donors were positive for HHV-7, but HHV-7 was rarely found in tumor samples of patients with B cell malignancies. For patients as well as for healthy donors, HHV-7 was logically found in samples known to contain T cells, such as preparations of purified T cells (3/5, not shown), PBL (2/4) and BM mononuclear cells (1/3) ( Table 3 ). All preparations of purified B lymphocytes and CD34 + cells were negative for HHV-7. Accordingly, only one MM and one B-ALL sample were positive for HHV-7, but HHV-7 was found in four out of 16 AML samples, all containing less than 100 copies/100 ng DNA. Similarly, few samples were positive for HHV-6 type B. HHV-6B was found mainly in PBL of control children (4/7); all B-ALL samples from children were negative. For adults, HHV-6B was detected in samples of only one healthy donor, three B-CLL patients, one MM patient and one B-ALL patient. The highest HHV-6B load was 35 copies/100 ng DNA.
The infection rates for HHV-6 type A were very different. All samples from healthy donors, children and adults, were negative for HHV-6A, as were all but one MM sample. In contrast, a significant proportion of samples of patients with either B-ALL (43.8%, P = 0.014), B-CLL (52.4%, P = 0.009) or AML (37.5%, P = 0.027) was positive for HHV-6A. Except for one B-CLL sample, HHV-6A DNA loads were Յ50 copies/100 ng DNA. The presence of HHV-6A was verified by standard PCR amplification of the DNA polymerase. To confirm HHV6-A positivity, four samples (3 B-CLL, 1 B-ALL) positive for HHV-6A by qPCR were submitted to standard PCR ( Figure 1) ; all four PCRs were positive and sequencing of the PCR products revealed sequences identical to the HHV-6A DNA polymerase sequence in the database. The patients' HHV-6A sequences differed by two bases from the sequence found in the HSB2/HHV-6 cells used in the laboratory. In addition, for two other patients, the presence of HHV-6A was confirmed on second, separate DNA preparations from different aliquots of tumor cells, by both qPCR and standard PCR amplification of HHV-6A DNA polymerase followed by sequencing (data not PCR amplification of HHV-6A DNA polymerase. 100 ng of DNA from tumor cell samples found positive for HHV-6A DNA polymerase by qPCR were submitted to standard PCR for HHV-6A DNA polymerase (see Methods). PCR products (152 bp) were separated by electrophoresis in a 2.5% agarose gel and stained by ethidium bromide.
shown). Five patient samples were positive for both types A and B of HHV-6: three B-CLL, one adult B-ALL, one AML.
Measurements of CMV DNA loads
CMV loads were significantly different in patients and in healthy donors, and they also differed according to pathology (Tables 3 and 4) . Samples from healthy children were all negative for CMV and only one sample from a healthy adult was positive; all MM samples were also negative for CMV. In contrast, 47.6% of B-CLL samples (P = 0.038, compared to healthy adults) and 75% of B-ALL samples were positive for CMV (P = 0.007 compared to healthy adults). The rate of CMV positivity for AML samples was also high, 81.2% (P = 0.007). CMV loads were <100 copies/100 ng DNA for all B-ALL samples from children and all AML samples, as well as all but two B-CLL samples (one with 4850 copies/100 ng DNA). In contrast, six out of 16 of adults with B-ALL had blast samples containing more than 100 CMV copies/100 ng DNA, two out of 16 contained more than 500 CMV copies/100 ng DNA (up to 1300 copies/100 ng DNA) ( Table 3) . High (>500 copies/100 ng DNA) loads of CMV or/and EBV were observed in tumor cell samples of six adult patients with B-CLL (2/21, 9.5%) or B-ALL (4/16, 25%). CMV loads of samples from adult B-ALL patients were significantly higher than CMV loads of B-CLL (P = 0.013) or AML (P <0.001) samples (Table 4) . Additional aliquots of tumor cells were available for two patients with a positive CMV qPCR. For these two patients, the presence of CMV DNA was confirmed by qPCR on new DNA preparations from the second cell aliquots.
Measurements of viral DNA loads of other nonlymphocytic tropic HHVs (HHV-1, HHV-2, VZV)
All samples were also tested by qPCR for the three other, nonlymphotropic HHVs: herpes simplex virus-1 (HHV-1), herpes simplex virus-2 (HHV-2) and varicella-zoster virus (VZV). Two B-CLL samples were positive for HHV-1 (loads: 3 and 7
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copies/100 ng DNA); two samples (1 AML, 1 B-CLL) were positive for HHV-2 (respective loads: 1 and 2 copies/100 ng DNA) and five samples (1 healthy donor, 1 MM and 3 B-ALL: 1 adult and 2 children, one with clinical symptoms of varicella) were positive for VZV (respective numbers of VZV copies/100 ng DNA: 2, 2, 6, 6 and for the patient with clinical symptoms, 370).
CODEHOP PCR for HHVs
Twenty samples (9 B-CLL, 7 MM, 4 B-ALL) were selected for CODEHOP PCR because of their negative or low viral loads of known HHVs as determined by qPCR. Most of the selected MM samples contained no HHVs, two contained HHV-6A (load: 1 and 4 copies/100 ng DNA); all the B-ALL samples were positive for CMV (loads: 2, 7, 17 and 74 copies/100 ng DNA), as were two B-CLL samples (loads: 2 and 7 copies/100 ng DNA); two other B-CLL samples were positive for EBV (loads: 4 and 15 copies/100 ng DNA), three were positive for HHV-6A (each 1 copy/100 ng DNA). As described in Methods, preliminary experiments determined that the lowest number of copies detectable by CODEHOP PCR, when performed in triplicate, was 10 for EBV, 100 for CMV and 1000 for HHV-6. Hence, we could predict that CODEHOP PCR would detect EBV in at least one sample, and possibly CMV in another sample. Two series of CODEHOP PCRs were performed, one with the DFAS primers designed to detect ␣-and ␥-HHVs, the other with the DFQS primers designed to detect ␤-HHVs (Table 2) . CODEHOP PCRs were negative for 16 of the 20 samples tested (6 B-CLL, 6 MM, all 4 B-ALL). One or both CODEHOP PCRs were positive for the other four samples (3 B-CLL, 1 MM). Sequencing of the PCR products revealed EBV sequences; two of the B-CLL samples were known to be positive for EBV by qPCR. No sequence compatible with a novel HHV was found.
Discussion
This study allows several conclusions: first, our data confirm other reports 31, 32 that, except for a particular patient with an unusual presentation of primary plasma cell leukemia (PCL), 27 HHV-8 is absent from MM plasma cells. They also show the absence of HHV-7 and HHV-6 type B in B-CLL, MM and B-ALL; because of their T cell tropism, it should be of interest to measure loads of these two viruses in T cell pathologies.
The second finding is that, at diagnosis, infection by HHV-6A and HHV-8 (adults only, all HIV-negative) appears more frequent in B-ALL, B-CLL or AML patients than reported in the general population of western Europe and the USA. 25, 26 The increased rate of positivity could be due to a higher sensitivity of our PCR techniques; this would imply that rates of HHV-8 and HHV-6A infection in the general population are currently underestimated. Another explanation, more appealing given the low rates of positivity in our control and MM series, is that patients with B-CLL, B-ALL or AML actually have a higher rate of HHV-8 and HHV-6A infection prior to the diagnosis of leukemia, and/or that during the leukemic process the two viruses become re-activated -thus, more easily detected by PCR techniques. However, all measurements reported here were made on cell-associated HHVs and status of latency vs productive infection were not addressed.
A third finding is that cell-associated viral DNA loads for EBV and particularly CMV vary depending on pathology. ConLeukemia trol samples from healthy donors and AML patients had low EBV loads and very low loads of CMV, a virus which can infect several cell types, particularly granulocytes, monocytes, and hematopoietic progenitors. B-CLL and MM samples were also characterized by low loads of both EBV and CMV; MM samples tested negative for CMV. In contrast, B-ALL samples of adults had high cell-associated CMV loads; 25% had high loads of EBV or/and CMV. Of particular interest is the high rate of CMV positivity (>75%) of B-ALL samples from children. The rates of CMV seropositivity in the general population in western Europe is approximately 50% for adults and less than 30% for children under 12. It can be argued that re-activation of CMV during the leukemic process may render CMV more easily detectable. Because CMV may exert an anti-tumoral action and has the potential to transactivate replication of other viruses, 33, 34 further investigation of the role played by CMV in B-ALL is warranted.
HHVs may disrupt immune functions or/and induce mutations in infected cells. HHVs, alone or associated with other viruses, can transform cells even as a consequence of a transient infection, in a 'hit-and-run' manner, during an abortive viral cycle when expression of specific viral genes induces mutations in the host genome. 35, 36 Independent of their potential role in cell transformation, re-activation of presumably latent HHVs during the course of anti-leukemia treatment can occur, usually explained by suppression of immune functions in aggressively treated patients. HHV-8 is now recognized as a cause of fever, hepatitis and, with HHV-6 and CMV, of delayed hematopoietic recovery or bone marrow failure in immunosuppressed patients. [37] [38] [39] [40] Thus, an increased rate of positivity for HHV-6A, HHV-8 and CMV in leukemic patients raises several questions. Are these viruses found more frequently in leukemic patients because of a specific immune dysfunction toward HHVs? The negativity for all three HHVs of MM patients, who are also severely immunocompromised, argues against the possibility that a globally impaired immunity in B-ALL, AML and B-CLL patients solely explains their increased rate of HHV positivity. The processes of B-ALL or B-CLL induction may render affected individuals more susceptible to infection by HHVs, or to their reactivation from latency; in addition, dual herpesvirus infection can result in a synergistic effect on viral expression. 34 In the near future, it is possible that the discovery at diagnosis of a high load of a HHV associated with a specific blood disorder will alert clinicians to significantly alter the treatment of this particular disease. In particular, quantitative studies during the course of the disease should establish whether B-ALL patients with high loads of EBV and CMV at diagnosis face an elevated risk of complications during treatment. [37] [38] [39] [40] [41] [42] [43] Equally intriguing is the possibility of detecting particular patterns of virus expression and levels of cell-associated viral loads before any clinical sign of disease appears, as has been described for HHV-8 and Kaposi's sarcoma, 44 which obviously could further improve treatment efficacy. A recent study reported that B-CLL patients are five times more likely to develop Kaposi's sarcoma than healthy controls. 45 Finally, if one assumes that to be directly responsible for transformation, at least one copy of HHV per cell (ie a viral load Ն10 4 copies/100 ng DNA) is necessary, only two patients (1 B-CLL, 1 B-ALL, with respectively, 10 3 and 2.2 × 10 3 copies of EBV/100 ng DNA) approached this level. Therefore, our study confirms the conclusion of a previous study limited to childhood ALL 46 that, taken separately, none of the HHVs found in B-ALL and B-CLL is present at levels high enough to be held responsible for B cell transformation. This was the rationale for trying to identify a novel B cell tropic herpesvirus directly responsible for B cell transformation. In agreement with MacKenzie et al, 46 our CODEHOP PCR results argue strongly against this hypothesis. It could be that a novel HHV may have a different DNA polymerase sequence rendering it undetectable by CODEHOP primers, but this seems unlikely given that CODEHOP primers are capable of amplifying herpesvirus DNA polymerases from reptiles to humans. [13] [14] [15] [16] [17] This study does not exclude, however, that a novel HHV may have been present in the samples tested, if the numbers of viral copies present were very low -below the detection limits of our PCR techniques.
In conclusion, this study shows that it is appropriate to hypothesize that for some patients HHVs may influence B-CLL and B-ALL clinical course. Further prospective studies should be valuable in determining whether high loads of HHVs found at diagnosis in leukemic cell samples are predictive of a poor prognosis and/or of the length of aplasia following chemotherapy, the quality and/or length of remission.
